[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345072-105":59,"doc-detail-345072-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","a-lat1-compatible-leadlike-tyrosine-naphthoquinone-conjugate-with-anticancer-activity","A LAT1-Compatible, Leadlike Tyrosine-Naphthoquinone Conjugate With Anticancer Activity","","A LAT1-compatible, anticancer-active tyrosine-naphthoquinone (NQ) conjugate was developed to exploit LAT1 overexpression in cancers and achieve selective cytotoxicity for cancerous versus noncancerous cells. The tyrosine-NQ molecule underwent cell viability, imaging, docking, and in silico pharmacological studies, plus structure-activity relationship (SAR) assessment including IC50 and substrate-competition. Results showed pronounced cytotoxic selectivity toward PC3 over HEK293, with comparable activity to NQ and doxorubicin (DOX). Docking supported LAT1 compatibility through interaction with transport pathway residues, and competition confirmed LAT1-facilitated uptake. SAR linked anticancer activity to an aryloxy-naphthoquinone motif. In silico work classified the conjugate as leadlike, and imaging revealed drug-induced stress responses in nuclear morphology, supporting its promise as a LAT1-targeting NQ-based chemotherapeutic lead.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/a-lat1-compatible-leadlike-tyrosine-naphthoquinone-conjugate-with-anticancer-activity/345072/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/a-lat1-compatible-leadlike-tyrosine-naphthoquinone-conjugate-with-anticancer-activity/345072.png","ImageObject",300,407,{"name":92,"@type":93},"Hazel","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-06","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main goal of developing the LAT1-compatible tyrosine-NQ conjugate?","Question",{"text":112,"@type":113},"To exploit LAT1 overexpression in cancers and achieve selective cytotoxicity for cancer cells over noncancerous cells.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was anticancer activity evaluated in the study?",{"text":117,"@type":113},"Through cell viability assays including IC50 and substrate-competition studies, supported by imaging, docking, and in silico pharmacological analyses with SAR assessment.",{"name":119,"@type":110,"acceptedAnswer":120},"What evidence supports that the conjugate is LAT1-compatible and uses LAT1-facilitated uptake?",{"text":121,"@type":113},"Docking showed interactions with key residues along LAT1’s transport pathway, and viability competition studies verified LAT1-facilitated uptake.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},345072,1790145934,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":41,"preview_page_count":19,"preview_urls":145},137441390410,"https://ap-avatar.wpscdn.com/avatar/2000252f4ab5702993?_k=1776741390130283984","Drug Development Research   \nRESEARCH ARTICLE   \nA LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity  \nAustin Seymour1 | Christian Peterson1 | Raymond Osafo1 | Abdullahi A. Ashimi1 | Dylan Williams1 | Laura Echezabal1 | Chelsea Carrier1 | Alysa Clarke1 | Clifford W. Padgett2 | Mark Vincent C. dela Cerna2 | Zheni Utic3,4 | Divine Wanduku4,5 | Nathaniel Shank2 | Karelle S. Aiken1  | Jannet Kocerha1  \n1Biochemistry, Chemistry, and Physics Department, Georgia Southern University, Statesboro, Georgia, USA | 2Biochemistry, Chemistry, and Physics Department, Science Center, Georgia Southern University, Savannah, Georgia, USA | 3Mathematical Sciences Department, University Hall, Georgia Southern University, Savannah, Georgia, USA | 4Statistical Consulting Unit (SCU), Department of Mathematical Sciences, Statesboro, Georgia, USA | 5Mathematical Sciences Department, Georgia Southern University, Statesboro, Georgia, USA  \nCorrespondence: Karelle S. Aiken ([kaiken@georgiasouthern.edu](kaiken@georgiasouthern.edu)) | Jannet Kocerha ([rkocerha@georgiasouthern.edu](rkocerha@georgiasouthern.edu))  \nReceived: 20 August 2025 | Revised: 1 March 2026 | Accepted: 17 March 2026  \nFunding: National Institutes of Health, Grant/Award Number: 1R15CA277652-01  \nKeywords: L‐type amino acid transporter 1 (LAT1) | leadlike | tyrosine‐naphthoquinone conjugate  \nABSTRACT  \nA L‐type amino acid transporter 1 (LAT1)‐compatible, anticancer‐active tyrosine‐naphthoquinone (NQ) conjugate was successfully developed. The conjugate was designed to exploit LAT1 overexpression in cancers with the goal of achieving selective cytotoxicity for cancerous over noncancerous cells. The tyrosine‐NQ molecule was subjected to cell viability, imaging, docking and in silico pharmacological studies along with structure‐activity relationship (SAR) assessment. Cell viability investigations included IC50 and substrate‐competition studies. Cells of cancerous (PC3) and noncancerous (HEK293) origin with high and minimal expressions of LAT1, respectively, were employed for biochemical investigations. The tyrosine‐NQ assembly showed significant cytotoxic selectivity toward PC3 over HEK293, with activity comparable to that of the parent molecule NQ and doxorubicin (DOX), an approved drug. Docking studies demonstrated that the conjugate is LAT1‐compatible as it interacts with key residues along the protein's transport pathway. Cell viability competition studies verify a LAT1‐facilitated uptake. SAR studies revealed that the conjugate's anticancer activity is due to its aryloxy‐naphthoquinone motif. In silico pharmacological investigations determined that the conjugate is leadlike and therefore, well‐suited for structural modifications for further drug development. Finally, imaging investigations showed that, with PC3, the conjugate caused drug‐induced stress‐responses in nuclear morphology. Overall, findings demonstrate that the tyrosine‐NQ conjugate is a promising lead for the design of LAT1‐targeting, NQ‐based chemotherapeutics.  \n1 | Introduction  \nThe L‐type amino acid transporter 1 (LAT1), also known as SLC7A5, is a transport protein that is significantly overexpressed in cancer cells to facilitate atypical nutritional needs (Scalise et al. 2018) . Due to its distinctive role in cancer pathology, targeting LAT1, through inhibition or drug transport, is an effective strategy for chemotherapeutic design.  \nGenerally, healthy cells exhibit low to non‐existent expression of LAT1; exceptions include the blood‐brain and placenta‐blood barriers (Scalise et al. 2018) . In contrast, reports have shown that cancers are dependent on LAT1 for processes such as tumor formation and growth, metastasis, and drug‐resistance (Scalise et al. 2018; Segawa et al. 2013) . In prostate cancers, for example, LAT1 expression is positively correlated with malignancy (Segawa et al. 2013) .  \nThis is an open access article under the terms of the Creative Commons Attribution‐NonComme","cbCaichyjBcU43bN","https://ap.wps.com/l/cbCaichyjBcU43bN","pdf",4638359,12,"English","# Introduction\n## LAT1 as a cancer target\n# Abstract\n## Conjugate design and rationale\n## Experimental evaluation (viability, imaging, docking)\n## SAR and in silico pharmacology\n## Key findings and implications","[{\"question\":\"What was the main goal of developing the LAT1-compatible tyrosine-NQ conjugate?\",\"answer\":\"To exploit LAT1 overexpression in cancers and achieve selective cytotoxicity for cancer cells over noncancerous cells.\"},{\"question\":\"How was anticancer activity evaluated in the study?\",\"answer\":\"Through cell viability assays including IC50 and substrate-competition studies, supported by imaging, docking, and in silico pharmacological analyses with SAR assessment.\"},{\"question\":\"What evidence supports that the conjugate is LAT1-compatible and uses LAT1-facilitated uptake?\",\"answer\":\"Docking showed interactions with key residues along LAT1’s transport pathway, and viability competition studies verified LAT1-facilitated uptake.\"}]","A LAT1-Compatible, Leadlike Tyrosine-Naphthoquinone Conjugate With Anticancer Activity | PDF",1790056423,[146,150,154,158],{"page_no":8,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d5a27dfc2c90fe0a835d83ed090092ca.webp",983,1291,{"page_no":14,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0c8e1bf3b1f140af00d6dea6df8d148.webp",982,1290,{"page_no":81,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/21dea1c040fc5f311033bb474b101082.webp",981,1289,{"page_no":19,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a97ae819b37d89cafe043a8692bd69db.webp",980,1287]